“Sharp” funding cuts disrupt PrEP access to millions of HIV patients
While the WHO is still assessing the scale of the impact of foreign aid cuts, access to PrEP medication is believed to have dropped dramatically.
Therapy Area
Dupixent gains chronic spontaneous urticaria indication in Europe
Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club
“Reckless and harmful”: experts weigh in on CDC’s autism-vaccine link stance
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
Regeneron’s Eylea franchise boosted by pair of FDA approvals
Pfizer and Tris reach settlement with Texas over ADHD drug allegations
Arrowhead nets first commercial win as siRNA drug garners FDA approval
